Lakefront Biotherapeutics (LKFT) Shares Outstanding (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Shares Outstanding (Entity) of $207.5 million for Q2 2020, up 18.26% year-over-year from $175.4 million in Q3 2019, and up 112431.55% quarter-over-quarter from $184365.0 in Q4 2019.
Lakefront Biotherapeutics (LKFT) Shares Outstanding (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Shares Outstanding (Entity) for 6 consecutive years, with $207.5 million the latest figure, recorded in Q2 2020.
- In Q2 2020, Shares Outstanding (Entity) rose 18.26% year-over-year to $207.5 million; the TTM figure through Jun 2020 stood at $207.5 million (up 18.26% YoY), while the FY2019 annual figure was $184365.0, down 99.89% from the prior year.
- Shares Outstanding (Entity) rose to $207.5 million in Q2 2020 per LKFT's latest filing, from $184365.0 in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $207.5 million in Q2 2020 and bottomed at $184365.0 in Q4 2019.
- Historically, Shares Outstanding (Entity) has averaged $147.5 million across 5 years, with a median of $156.0 million in 2017.
- Annual changes were most pronounced in 2016 — Shares Outstanding (Entity) rose 28.0% — and 2019, when it tumbled 99.89%.
- Lakefront Biotherapeutics' Shares Outstanding (Entity) stood at $146.2 million in 2016, then increased by 8.28% to $158.3 million in 2017, then climbed by 5.32% to $166.8 million in 2018, then sank by 99.89% to $184365.0 in 2019, then surged by 112431.55% to $207.5 million in 2020.
- Business Quant data shows LKFT's Shares Outstanding (Entity) at $207.5 million in Q2 2020, $184365.0 in Q4 2019, and $175.4 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 65.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.90 Mn |
| Dec 31, 2025 | 65.90 Mn |
| Sep 30, 2025 | 65.90 Mn |
| Jun 30, 2025 | 65.90 Mn |
| Mar 31, 2025 | 65.90 Mn |
| Dec 31, 2024 | 65.90 Mn |
| Sep 30, 2024 | 65.90 Mn |
| Jun 30, 2024 | 65.90 Mn |
| Mar 31, 2024 | 65.88 Mn |
| Dec 31, 2023 | 65.88 Mn |
| Sep 30, 2023 | 65.70 Mn |
| Jun 30, 2023 | 65.70 Mn |
| Mar 31, 2023 | 65.70 Mn |
| Dec 31, 2022 | 65.70 Mn |
| Sep 30, 2022 | 65.50 Mn |
| Jun 30, 2022 | 65.50 Mn |
| Mar 31, 2022 | 65.50 Mn |
| Dec 31, 2021 | 65.50 Mn |
| Sep 30, 2021 | 65.47 Mn |
| Jun 30, 2021 | 65.47 Mn |